Article

Mutated Processes Predict Immune Checkpoint Inhibitor Therapy Benefit in Metastatic Melanoma

2022-02-02

Abstract excerpt

Immune Checkpoint Inhibitor (ICI) therapy has revolutionized treatment for advanced melanoma; however, only a subset of patients benefit from this treatment. Despite considerable efforts, the Tumor Mutation Burden (TMB) is the only U.S. Food and Drug Administration (FDA) approved biomarker for ICI treatment in melanoma. However, the mechanisms underlying TMB association with prolonged ICI survival are not entirely...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d553efc6-5ff1-59eb-b9ef-b59f50fecb62
DOI: 10.21203/rs.3.rs-1269101/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mutated Processes Predict Immune Checkpoint Inhibitor Therapy Benefit in Metastatic MelanomaDOI 10.21203/rs.3.rs-1269101/v1Read

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.Semantic proximity Read

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanomaSemantic proximity Read

Transcriptional analysis of immune modulatory genes in melanoma treated with PD-1 blockadeSemantic proximity Read

Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.Semantic proximity Read

Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.Semantic proximity Read

A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.Semantic proximity Read

Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.Semantic proximity Read

Gene expression and immune infiltration in melanoma patients with different mutation burden.Semantic proximity Read

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read